- Dr. Larrieux brings significant experience managing analytical development quality control of immunotherapies to treat cancer and small molecule therapies at pharmaceutical and biotechnology organizations
Actinium
Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a
biopharmaceutical company developing innovative targeted therapies for
cancers lacking effective treatment options, announced today that
Jeannine Larrieux, Ph.D. has been appointed Director of Analytical
Development. Dr. Larrieux will be responsible for analytical assay
development, conducting biologics license application (BLA) and
investigational new drug (IND) enabling studies, authoring CMC
analytical sections for BLA and IND filings and supporting both internal
and external quality assurance (QA) and quality control (QC) efforts.
“Dr.
Larrieux is an accomplished analytical professional who is bringing
over 20 years of highly relevant industry experience in matters related
to regulatory submissions, project management and QA/QC to Actinium,”
said Sandesh Seth, Actinium’s Executive Chairman. “Dr. Larrieux is yet
another invaluable addition to the Actinium team that will contribute
enormously to the development of our clinical programs Iomab-B and
Actimab-A as well as future clinical programs we hope to unveil in the
near future.”
Dr. Larrieux joins Actinium
following analytical consulting assignments in the U.S. and Europe.
Prior to this, she was Head of AS&T at Novartis where she focused on
cell therapy products aimed to treat acute lymphoblastic leukemia (ALL)
and chronic lymphocytic leukemia (CLL). Prior to Novartis, Dr. Larrieux
was Laboratory Manager at Dendreon Corporation where she supported
Phase 3 and Phase 4 clinical studies. In addition, Dr. Larrieux has
worked at Pfizer, Purdue Pharma and Wyeth in analytical roles.
Dr.
Larrieux earned her Ph.D. in Material Chemistry from Polytechnic
Institute of NYU, an M.S. degree in Chemistry from Polytechnic
University and a BS.c. degree in Chemistry from State University of
HAITI (PAP). In addition, she is a member of the Regulatory Affairs
Professionals Society (RAPS) and a member of the American Society for
Quality (ASQ).
About Actinium Pharmaceuticals, Inc.
Actinium
Pharmaceuticals, Inc. is a biopharmaceutical company developing
innovative targeted therapies for patients with cancers lacking
effective treatment options. Actinium's proprietary platform utilizes
monoclonal antibodies to deliver radioisotopes directly to cells of
interest in order to kill those cells safely and effectively. The
Company's lead product candidate Iomab-B is designed to be used, upon
approval, in preparing patients for a hematopoietic stem cell
transplant, commonly referred to as bone marrow transplant. A bone
marrow transplant is often the only potential cure for patients with
blood-borne cancers but the current standard preparation for a
transplant requires chemotherapy and/or total body irradiation that
result in significant toxicities. Actinium believes Iomab-B will enable a
faster and less toxic preparation of patients seeking a bone marrow
transplant, leading to increased transplant success and survival rates.
The Company is currently conducting a single pivotal 150-patient,
multicenter Phase 3 clinical study of Iomab-B in patients with relapsed
or refractory acute myeloid leukemia (AML) age 55 and older. The
Company's second product candidate, Actimab-A, is currently in a
multicenter open-label, 53-patient Phase 2 trial for patients newly
diagnosed with AML age 60 and over. Actimab-A is being developed to
induce remissions in elderly patients with AML who lack effective
treatment options and often cannot tolerate the toxicities of standard
frontline therapies. Actinium is also utilizing its alpha-particle
immunotherapy (APIT) technology platform to generate new drug candidates
based on antibodies linked to the element Actinium-225 that are
directed at various cancers that are blood-borne or form solid tumors.
Actinium Pharmaceuticals is based in New York, NY. To learn more about
Actinium Pharmaceuticals, please visit www.actiniumpharma.com and to follow @ActiniumPharma on Twitter please visit, www.twitter.com/actiniumpharma.
No comments:
Post a Comment